Drug Profile
Research programme: PPAR delta agonists - ABIONYX Pharma/Nippon Chemiphar
Alternative Names: NP-016; NP-022; PPARδ agonists - ABIONYX Pharma/Nippon ChemipharLatest Information Update: 11 Sep 2019
Price :
$50
*
At a glance
- Originator Nippon Chemiphar
- Developer ABIONYX Pharma; Nippon Chemiphar
- Class Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Low HDL cholesterol
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Low-HDL-cholesterol in France (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Low-HDL-cholesterol in Japan (PO)
- 04 Sep 2008 Pharmacokinetics and pharmacodynamics data from a preclinical trials in Low HDL cholesterol presented at the 20th International Symposium on Medicinal Chemistry (ISMC-20008)